Standout Papers

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with i... 2013 2026 2017 2021 925
  1. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial (2013)
    Mathias Rummel, N. Niederle et al. The Lancet

Immediate Impact

2 by Nobel laureates 2 from Science/Nature 59 standout
Sub-graph 1 of 22

Citing Papers

Catalytic Asymmetric Construction of Chiral Polysubstituted 3-Azabicyclo[3.1.1]heptanes by Copper-Catalyzed Stereoselective Formal [4π+2σ] Cycloaddition
2024 Standout
Mitochondria in health, disease, and aging
2023 Standout
2 intermediate papers

Works of Gamal-Andre Banat being referenced

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013 Standout
Role of Epidermal Growth Factor Inhibition in Experimental Pulmonary Hypertension
2009

Author Peers

Author Last Decade Papers Cites
Gamal-Andre Banat 704 181 209 860 515 12 1.3k
Christina Balser 878 147 79 1254 802 18 1.5k
Heinz Dürk 958 142 132 1206 740 30 1.7k
B. Christian 603 115 111 938 356 8 1.2k
Jane Donaldson 568 107 136 883 320 14 1.1k
Hwee‐Yong Yap 760 179 202 148 270 31 1.3k
Steve Alas 547 322 406 648 397 7 1.2k
Miriam Tucker 708 30 493 392 122 7 1.5k
Virginie Lucas 768 106 129 421 117 24 1.1k
Akintunde Akinleye 729 336 648 291 241 13 1.5k
Wilfried J. Graveland 816 135 381 209 336 27 1.7k

All Works

Loading papers...

Rankless by CCL
2026